Literature DB >> 10419558

Interactions of HIV protease inhibitors with ATP-dependent drug export proteins.

H Gutmann1, G Fricker, J Drewe, M Toeroek, D S Miller.   

Abstract

We used renal proximal tubules from a teleost fish (killifish; Fundulus heteroclitus), fluorescent substrates and confocal microscopy to study the interactions between human immunodeficiency virus protease inhibitors and drug-transporting ATPases. Both saquinavir and ritonavir inhibited luminal accumulation of a fluorescent cyclosporin A derivative (a substrate for P-glycoprotein) and of fluorescein methotrexate [a substrate for multidrug resistance-associated protein 2 (Mrp2)]. Of the two protease inhibitors, ritonavir was the more potent inhibitor of transport by a factor of at least 20. Ritonavir was at least as good an inhibitor of P-glycoprotein- and Mrp2-mediated transport as cyclosporin A and leukotriene C4, respectively. Inhibition of P-glycoprotein- and Mrp2-mediated transport was not due to toxicity or impaired metabolism, because neither saquinavir nor ritonavir inhibited transport of fluorescein on the renal organic anion system. Experiments with a fluorescent saquinavir derivative showed strong secretion into the tubular lumen that was inhibited by verapamil, leukotriene C4, saquinavir, and ritonavir. Together, the data demonstrate that saquinavir, and especially ritonavir, are potent inhibitors of P-glycoprotein- and Mrp2-mediated transport. The experiments with the fluorescent saquinavir derivative suggest that these protease inhibitors may also be substrates for both P-glycoprotein and Mrp2.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10419558     DOI: 10.1124/mol.56.2.383

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  34 in total

Review 1.  The role of therapeutic drug monitoring in treatment of HIV infection.

Authors:  D J Back; S H Khoo; S E Gibbons; C Merry
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

Review 2.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

3.  Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide.

Authors:  Mikko Niemi; Aleksi Tornio; Marja K Pasanen; Hanna Fredrikson; Pertti J Neuvonen; Janne T Backman
Journal:  Eur J Clin Pharmacol       Date:  2006-04-27       Impact factor: 2.953

4.  Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.

Authors:  Yoko Honda; Fumihiko Ushigome; Noriko Koyabu; Satoshi Morimoto; Yukihiro Shoyama; Takeshi Uchiumi; Michihiko Kuwano; Hisakazu Ohtani; Yasufumi Sawada
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

5.  Determination of intracellular unbound concentrations and subcellular localization of drugs in rat sandwich-cultured hepatocytes compared with liver tissue.

Authors:  Nathan D Pfeifer; Kevin B Harris; Grace Zhixia Yan; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2013-08-29       Impact factor: 3.922

6.  Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity.

Authors:  Soichi Haraguchi; Sarah K Ho; Matthew Morrow; Maureen M Goodenow; John W Sleasman
Journal:  J Leukoc Biol       Date:  2011-04-19       Impact factor: 4.962

7.  Ivermectin excretion by isolated functionally intact brain endothelial capillaries.

Authors:  S Nobmann; B Bauer; G Fricker
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

8.  Differential bidirectional transfer of indinavir in the isolated perfused human placenta.

Authors:  Sreeja Sudhakaran; Hany Ghabrial; Roger L Nation; David C M Kong; Neil M Gude; Peter W Angus; Craig R Rayner
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

9.  Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier.

Authors:  Corbin J Bachmeier; Timothy J Spitzenberger; William F Elmquist; Donald W Miller
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

10.  The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.

Authors:  Omar Janneh; Andrew Owen; Patrick G Bray; David J Back; Munir Pirmohamed
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.